Zacks Research Has Bullish Forecast for CPRX Q1 Earnings

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Zacks Research upped their Q1 2025 earnings estimates for Catalyst Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of $0.49 per share for the quarter, up from their prior estimate of $0.44. The consensus estimate for Catalyst Pharmaceuticals' current full-year earnings is $1.90 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals' Q2 2025 earnings at $0.51 EPS, Q3 2025 earnings at $0.49 EPS, Q4 2025 earnings at $0.53 EPS, Q1 2026 earnings at $0.57 EPS, Q2 2026 earnings at $0.55 EPS and Q4 2026 earnings at $0.57 EPS.

Other equities analysts have also recently issued reports about the stock. Bank of America restated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Robert W. Baird upped their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $32.29.

Remove Ads

Catalyst Pharmaceuticals Trading Down 0.1 %

NASDAQ CPRX traded down $0.02 during midday trading on Friday, hitting $25.72. The company had a trading volume of 1,742,618 shares, compared to its average volume of 1,063,389. Catalyst Pharmaceuticals has a twelve month low of $14.47 and a twelve month high of $26.16. The firm has a 50-day moving average price of $22.46 and a 200-day moving average price of $21.67. The company has a market capitalization of $3.12 billion, a PE ratio of 21.80, a P/E/G ratio of 3.31 and a beta of 0.84.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in CPRX. Castlekeep Investment Advisors LLC bought a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $37,494,000. Bank of America Corp DE boosted its position in shares of Catalyst Pharmaceuticals by 139.5% during the fourth quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after buying an additional 913,843 shares during the last quarter. abrdn plc bought a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $10,115,000. Arrowstreet Capital Limited Partnership raised its position in Catalyst Pharmaceuticals by 131.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock valued at $14,570,000 after buying an additional 396,506 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after acquiring an additional 390,116 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.